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Abstract
Recombinant adeno-associated viruses (rAAVs) are commonly used vehicles for in vivo gene 
transfer1-6. However, the tropism repertoire of naturally occurring AAVs is limited, prompting a 
search for novel AAV capsids with desired characteristics7-13. Here we describe a capsid selection 
method, called Cre-recombination-based AAV targeted evolution (CREATE), that enables the 
development of AAV capsids that more efficiently transduce defined Cre-expressing cell 
populations in vivo. We use CREATE to generate AAV variants that efficiently and widely 
transduce the adult mouse central nervous system (CNS) after intravenous injection. One variant, 
AAV-PHP.B, transfers genes throughout the CNS with an efficiency that is at least 40-fold greater 
than that of the current standard, AAV914-17, and transduces the majority of astrocytes and neurons 
across multiple CNS regions. In vitro, it transduces human neurons and astrocytes more efficiently 
than does AAV9, demonstrating the potential of CREATE to produce customized AAV vectors for 
biomedical applications.
rAAVs are the preferred vehicles for many in vivo gene transfer applications to non-dividing 
cell populations and are proving safe in clinical trials18-20. However, therapeutic applications 
have been limited by inefficient transduction of target cell populations. A prime example is 
gene transfer to the CNS; the transduction efficiency of currently available vectors in the 
mouse CNS after intravenous administration is at least an order of magnitude lower than in 
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the liver21. Encouragingly, the transduction efficiency of rAAVs can be enhanced by creating 
AAV capsid libraries and selecting for variants with more desirable characteristics8-13. This 
approach, however, has not been successfully applied to the development of more effective 
gene delivery vehicles for global CNS transduction. Because the highly selective blood brain 
barrier (BBB) and cellular heterogeneity of the CNS present challenges for gene transfer to 
the CNS through the vasculature, we reasoned that it would be beneficial to provide selective 
pressure for capsids that cross the BBB and functionally transduce specific cell types. To 
meet these needs, we devised CREATE—a Cre recombination-dependent approach to 
selectively recover capsids that transduce predefined Cre expressing target cell populations 
(Fig. 1a).
CREATE uses an rAAV capsid genome (rAAV-Cap-in-cis-lox) that couples a full-length 
AAV Cap gene, controlled by regulatory elements from the AAV Rep gene (Fig. 1b and 
Methods), with a Cre-invertible switch (Fig. 1b). By building capsid libraries within the 
rAAV-Cap-in-cis-lox backbone and delivering the virus libraries to animals with Cre 
expression in a defined cell population, the system enables the selective amplification and 
recovery of sequences that have transduced the target population (Fig. 1c). Because the 
rAAV-Cap-in-cis-lox genome lacks a functional Rep gene, Rep must be provided in trans for 
virus production. For this purpose, we modified an AAV2/9 rep-cap plasmid to eliminate 
capsid protein expression by inserting in-frame stop codons within the reading frame for 
each capsid protein, VP1-3 (Fig. 1d). These stop codons do not alter the amino acid 
sequence of the assembly-activating protein (AAP), which is expressed from an alternative 
reading frame within the Cap gene22. This split rAAV-Cap-in-cis-lox genome and Rep-AAP 
AAV helper system efficiently generates rAAV (Fig. 1e) and is the foundation of the 
CREATE selection platform, which enables capsid sequence recovery from genetically 
defined Cre-expressing cell populations within heterogeneous tissue samples (see 
Supplementary Fig. 1).
Within the rAAV-Cap-in-cis-lox acceptor genome we generated a library of AAV variants by 
inserting 7 amino acids (AA) of randomized sequence (7-mer) between AA588-589 (VP1 
position) of the AAV9 capsid (Fig. 1f, g). To select for vectors that crossed the BBB and 
transduced cells throughout the CNS, we administered the capsid library intravenously into 
adult GFAP-Cre mice, which express Cre in astrocytes23. One week later, we isolated DNA 
from brain and spinal cord tissue and recovered capsid sequences by PCR from viral 
genomes that had undergone Cre-mediated recombination. We cloned the entire library of 
recovered Cap sequences back into the rAAV-Cap-in-cis-lox acceptor genome to generate 
the library GFAP1 and randomly chose 13 clones for sequencing. All tested sequences 
recovered from the GFAP1 library were unique, and therefore we used the GFAP1 plasmid 
library to generate a second virus library and performed an additional round of selection in 
GFAP-Cre mice. After the second selection, several variants were enriched (Supplementary 
Table 2) and showed enhanced CNS transduction (Supplementary Fig. 2a). We chose the 
most enriched variant, AAV-PHP.B, which represented 25% of recovered library sequences 
and encodes the 7-mer sequence TLAVPFK, for further tropism evaluation in vivo.
AAV-PHP.B and AAV9 capsids were used to package a single-stranded (ss) GFP reporter 
vector driven by the ubiquitous CAG promoter (ssAAV-CAG-GFP). Both AAV-PHP.B and 
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AAV9 produced virus with similar efficiencies (Supplementary Fig. 2b). We next 
administered 1×1012 vector genomes (vg) of either vector to six-week-old mice by 
intravenous injection and assessed transduction by GFP expression three weeks later. Our 
data show that AAV-PHP.B transduced the entire adult CNS with high efficiency as indicated 
by imaging GFP immunohistochemistry (IHC) (Fig. 2a) or native eGFP fluorescence in 
several brain regions (Fig. 2b), the spinal cord (Fig. 2c) and retina (Fig. 2d). Using PARS-
based CLARITY for whole body tissue clearing24, we imaged native eGFP fluorescence 
through cleared sections of tissue from the spinal cord (Fig. 2c), cortex and striatum (Fig. 
2e). These 3D renderings (also see Supplementary Movies 1-3) further demonstrate the 
broad and efficient CNS transduction with the AAV-PHP.B vector. Outside the CNS, the 
cellular level tropism of AAV-PHP.B and AAV9 appeared similar in several organs, with the 
exception of the pancreas where the efficiency of transduction by AAV-PHP.B was reduced 
as compared with AAV9 (Fig. 2f).
To quantify the efficiency of gene transfer to the CNS and peripheral organs by AAV-PHP.B 
as compared with AAV9, we measured the number of viral genomes present in several brain 
regions and organs 25 days post-injection (Fig. 2g). AAV-PHP.B provided significantly 
greater gene transfer than AAV9 to each of the CNS regions examined: cortex (40-fold), 
striatum (92-fold), thalamus (76-fold), cerebellum (41-fold) and spinal cord (75-fold). 
Vector genome biodistribution outside the CNS showed that AAV-PHP.B transferred genes 
to the pancreas and adrenal gland less efficiently than AAV9 (Fig. 2g). No significant 
differences were found between the two vectors in the liver, heart, skeletal muscle and 
kidneys. When considered together with the CNS biodistribution data, in all CNS areas 
except the cerebellum, the number of viral genomes detected in mice treated with AAV-
PHP.B was similar to that measured in the liver, an organ efficiently transduced by 
AAV921,25, and greater than that observed in other organs. In contrast, AAV9-mediated gene 
transfer to each of the examined CNS regions was at least 120-fold lower than in the liver. 
Therefore, although the tropism of AAV-PHP.B is not CNS specific, the enhanced gene 
transfer characteristics of this vector are CNS specific.
AAV9 preferentially transduces astrocytes when delivered intravenously to adult mice and 
non-human primates, but it also transduces neurons in several regions14,26. To examine the 
cell types transduced by AAV-PHP.B, we analyzed the co-localization of GFP with several 
cell-type markers. Owing to the highly efficient transduction, individual GFP expressing 
astrocytes were difficult to discern in mice that received 1×1012 vg AAV-PHP.B (Fig. 2a), 
but could be more easily identified morphologically by their compact, highly ramified 
processes in animals that received 10-fold less virus (Fig. 2a, b) and by co-localization with 
IHC for GFAP (Fig. 3a). In addition to astrocytes, AAV-PHP.B transduced CC1+ 
oligodendrocytes (Fig. 3b) and all neuronal subtypes examined, including NeuN+ 
throughout the brain (Fig. 3c) as well as midbrain tyrosine hydroxylase (TH)+ dopaminergic 
neurons (Fig. 3d), Calbindin+ cerebellar Purkinje cells (Fig. 3e), and several interneuron 
populations (Supplementary Fig. 3a-d). AAV-PHP.B also transduced CD31+ endothelial 
cells (Supplementary Fig. 3e) but did not appear to transduce Iba1+ microglia 
(Supplementary Fig. 3f,g). The paucity of GFP+ microglia seen after intravenous AAV-
PHP.B delivery is consistent with previous reports of rare or nonexistent AAV-mediated gene 
Deverman et al. Page 3
Nat Biotechnol. Author manuscript; available in PMC 2016 October 31.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
expression in this cell population14,27-30. We have observed native GFP expression 
throughout the brain over a year after administration of AAV-PHP.B, suggesting that AAV-
PHP.B can provide long-term, CNS-directed transgene expression (Supplementary Fig. 4).
We next quantified the fraction of several cell types transduced by AAV-PHP.B as compared 
to AAV9. To facilitate reliable individual cell counting, we constructed a vector expressing a 
nuclear-localized GFP (NLS-GFP) under the control of the CAG promoter, ssAAV-CAG-
NLS-GFP. A single injection of 2×1012 vg/mouse of ssAAV-PHP.B:CAG-NLS-GFP 
transduced the majority of Aldh1L1+ astrocytes (Fig. 3f and Supplementary Fig. 5a) and 
NeuN+ neurons (Fig. 3g and Supplementary Fig. 5b), as well as a modest fraction of 
Olig2+ oligodendrocyte lineage cells (Fig.3h and Supplementary Fig. 5c) across all brain 
regions examined. In all cases, AAV-PHP.B provided significantly enhanced transduction as 
compared to the same dose of AAV9. Notably, AAV-PHP.B also transduced over 94% of 
Chat+ motor neurons throughout the spinal cord (Fig. 3i), 91.4±1.6% of TH+ midbrain 
dopaminergic neurons (Supplemental Fig. 5d) and 91.7±5.8% of Calbindin+ Purkinje cells 
(n=5). In sum, adult intravenous administration of AAV-PHP.B efficiently targets multiple 
neuronal and glial cell types in the adult mouse.
The method used to identify AAV-PHP.B only selects for transduction of the target cell 
population; it does not necessarily select for specificity. Nevertheless, in a separate trial in 
GFAP-Cre mice, we identified (after two rounds of in vivo selection) another AAV capsid 
variant, AAV-PHP.A, with the 7-mer sequence, YTLSQGW, that exhibits both more efficient 
and selective CNS astrocyte transduction (Fig. 4a-d), as well as reduced tropism for the liver 
(Fig. 4e, f) and other peripheral organs (Fig. 4f), as compared to AAV9. The increase in 
specificity for gene transfer to the CNS over the liver provided by AAV-PHP.A versus AAV9 
is 400- to 1200-fold, resulting from a combination of enhanced adult CNS gene transfer 
(2.6- to 8-fold more depending on the specific region) and reduced liver gene transfer (152-
fold). Two other variants enriched in this trial (Supplementary Fig. 2a) did not show 
enhanced GFP expression in CNS neurons or glia as compared with AAV9.
To determine whether AAV-PHP.A and AAV-PHP.B can also transduce human neural cells, 
we tested them on cortical neurons and astrocytes derived from human induced pluripotent 
stem cells (hiPSCs) using a 3D differentiation method31. HiPSC lines from two individuals 
were differentiated into 3D cerebral cortex-like structures (cortical spheroids), and 
maintained in vitro for up to 200 days. Aged cortical spheroids contain superficial and deep 
layer cortical excitatory neurons and up to 20% astrocytes31. In dissociated cortical 
spheroids that were exposed to the three viruses in monolayer, AAV-PHP.B more efficiently 
transduced both GFAP-expressing astrocytes and MAP2-expresing neurons in comparison 
with either AAV9 or AAV-PHP.A (Supplemental Fig. 5; two-way ANOVA p<0.01, n=3). In 
addition, all three viruses were capable of transducing intact 3D cortical spheroids 
(Supplementary Fig. 5c).
Using CREATE, we have developed new AAV variants that enable efficient widespread gene 
transfer to the adult mouse CNS after intravenous administration. An important advantage of 
this system is that it introduces selective pressure for capsids that mediate efficient 
intracellular trafficking and conversion of the single-stranded viral genome to persistent 
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double-stranded DNA (dsDNA) forms necessary for long-term transduction (only the 
dsDNA genomes should serve as substrates for Cre). This additional selective pressure for 
functional capsids may have contributed to the identification of AAV-PHP.A and the AAV-
PHP.B variants in independent trials after only two rounds of in vivo selection. In 
comparison, many previous in vivo and in vitro AAV capsid selection methods have applied 
3-10 rounds of selection to identify capsid variants with enhanced properties9-13,32.
In principle, CREATE could be applied to discover AAV capsid variants that target defined, 
CRE-expressing cell types in any organ. Thus, it could be used not only in transgenic 
animals, as shown here, but also to develop AAV variants that target (i) specific Cre+ cell 
types in spheroid cultures31 or organoid cultures, (ii) cells made Cre+ in non-transgenic 
animals by, for example, viral injections that achieve population-, projection33-, or activity-
based Cre expression34,35 or (iii) Cre+ human cells in human/mouse chimeric animals. 
Given the reported AAV tropism differences between animal models and humans11, 
selection schemes that use human Cre+ cells in vivo, cell-specific Cre expression in three-
dimensional hiPSC-derived cellular models, or future Cre transgenic marmosets36 may be 
desirable for developing improved vectors for clinical applications. In addition, the success 
of AAV-based gene therapies, especially those requiring systemic delivery, can be hindered 
by the presence of neutralizing AAV capsid antibodies in the human population37-39. By 
using CREATE together with exposure of AAV libraries to pooled human sera, one could 
envision simultaneously selecting for capsids with retained or enhanced transduction 
characteristics that are also less susceptible to antibody-mediated neutralization.
A limitation of CREATE and other reported capsid selection methods is that it is difficult to 
predict, beyond an increase in target cell transduction efficiency, what characteristics the 
enriched variants will have before they are tested. In our two trials for astrocyte targeting, we 
identified several variants, AAV-PHP.B, B2, and B3 (Supplementary Fig. 2) that provide 
broad CNS transduction of both neurons and glia, and AAV-PHP.A that provides selectively 
more efficient astrocyte transduction. Identification of capsids with distinct properties from 
the same selection scheme was expected given that the recovery method we used selected for 
astrocyte transduction rather than for any specific intermediate step(s), e.g., brain vascular 
association, BBB transcytosis or astrocyte binding/internalization. Therefore, capsid variants 
that are more efficient at any of these intermediate steps should be recovered in our selection 
process. Indeed, by immunostaining for capsids we found that unlike AAV9, both AAV-PHP 
capsids readily localized to the brain vasculature shortly after intravenous administration 
(Supplementary Fig. 7a, b). In addition, by 24 hours post-administration, significantly 
more GFP-expressing cells were observed along the brain vasculature of mice that received 
AAV-PHP.B as compared with those that received AAV9 or AAV-PHP.A (Supplementary 
Fig. 7c, d). Considered together with the transduction characteristics of AAV-PHP.B and 
AAV-PHP.A in vivo (Figs. 2-4) and in human neural cultures (Supplementary Fig. 6), these 
data suggest that while both AAV-PHP vectors more efficiently associate with the brain 
vasculature, they may differ in subsequent cell type-specific entry or transport step(s).
In the future, CREATE could be used with next-generation sequencing to better predict the 
characteristics of the recovered sequences prior to testing the variants individually. 
Sequencing both the entire pool of variants recovered from the Cre-expressing target cells 
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along with the unselected virus library should enable quantification of the relative extent of 
enrichment of each recovered sequence. Furthermore, sequencing capsids recovered from 
multiple Cre-expressing or Cre non-expressing populations could provide a means to 
perform both positive and negative selection in multiple cell types in a single experiment. 
Such in vivo-in silico selection approaches should increase the power of CREATE to 
enhance gene transfer to the CNS and other difficult-to-target cell populations.
METHODS
Plasmids
The rAAV-Cap-in-cis-lox genome plasmid contains three main elements flanked by AAV2 
ITRs: (i) an mCherry expression cassette, which is comprised of a 398bp fragment of the 
human UBC gene upstream of the mCherry cDNA followed by a synthetic polyadenylation 
sequence40; (ii) the AAV9 capsid gene and regulatory sequences, which are comprised of the 
AAV5 p41 promoter sequence (1680-1974 of GenBank AF085716.1)41,42 and splicing 
sequences taken from the AAV2 rep gene; and (iii) a Cre-dependent switch, which is 
comprised of the SV40 polyadenylation sequence (pA) flanked by inverted lox71 and lox66 
sites43 (Fig. 1b). The rAAV-Cap-in-cis-lox genome plasmid was further modified to 
introduce two unique restriction sites, XbaI and AgeI, within the capsid sequence. These 
sites flank the region (AA450-592) that is replaced by the randomized library fragment. The 
introduction of the XbaI site introduces a K449R mutation, which does not have an overt 
effect on vector production or transduction. The mutations required to insert the AgeI site 
are silent. For the rAAV-ΔCap-in-cis acceptor plasmid used for the capsid library cloning, 
the coding region between the XbaI and AgeI sites was removed to prevent virus production 
from the acceptor plasmid lacking the library fragment.
As a template for the library fragment, we PCR amplified the region spanning the XbaI and 
AgeI sites of the modified AAV9. This sequence was modified to remove a unique EarI 
restriction site and insert a unique KpnI site (both silent mutations) to create the xE 
fragment. The modified xE fragment was TA cloned into pCRII (Life Technologies) to 
generate pCRII-9Cap-xE. Eliminating the EarI site provided a second method that could be 
used, if necessary, to selectively digest contaminating (AAV9) capsid sequences recovered 
by PCR, but not digest the library-derived sequences. We did not find it necessary to use this 
digestion step. Using the rAAV-ΔCap-in-cis acceptor for cloning the libraries and taking 
standard PCR precautions (e.g., UV treating reagents and pipettors) was sufficient to prevent 
contamination.
The AAV2/9 REP-AAP helper plasmid was constructed by introducing five stop codons into 
the coding sequence of the VP reading frame of the AAV9 gene at VP1 AAs: 6, 10, 142, 148 
and 216. The stop codon at AA216 was designed not to disrupt the coding sequence of the 
AAP protein, which is encoded within an alternative reading frame.
Several rAAV genomes were used in this study. Each is constructed within a single stranded 
(ss) rAAV genome with a reporter driven by the ubiquitous CMV-β-Actin-intron-β-Globin 
hybrid promoter (CAG). For simplicity, the vector descriptions have been abbreviated in the 
text. ssAAV-CAG-GFP refers to ssAAV-CAG-eGFP-2A-Luc-WPRE-SV40 polyA. ssAAV-
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CAG-NLS-GFP refers to ssAAV-CAG-NLS-GFP-WPRE-SV40 polyA, which was 
constructed by inserting the nuclear localization sequence PKKKRKV at both the N- and C-
termini of GFP. ssAAV-CAG-mNeGreen-f refers to ssAAV-CAG-mNeonGreen-f-WPRE 
with a human growth hormone polyA signal. The mNeonGreen44 was modified with the 
membrane targeting (farnesylation and palmitoylation signals) sequence from c-Ha-Ras45.
Capsid library generation
The random 7-mer library fragment (inserted between amino acids 588 and 589) was 
generated by PCR using Q5 Hot Start High-Fidelity DNA Polymerase (NEB; M0493), 
primers XF and 7×MNN and pCRII-9Cap-xE as a template. A schematic showing the 
approximate primer binding sites and a table of the primer sequences are given in 
Supplementary Figure 1 and Supplementary Table 1, respectively. To generate the rAAV-
based library, the PCR products containing the library and the XbaI- and AgeI-digested 
rAAV-ΔCap-in-cis acceptor plasmid were assembled using Gibson Assembly (NEB; E2611). 
The reaction products were then treated with Plasmid Safe (PS) DNase (Epicentre; E3105K) 
to digest any unassembled fragments and purified using a QIAquick PCR Purification Kit 
(Qiagen). This reaction typically yielded over 100 ng of assembled plasmid (as defined by 
the amount of DNA remaining after the PS DNase digestion step). 100 ng is sufficient to 
transfect ten 150mm tissue culture dishes at 10 ng/dish. Note, the libraries can also be 
constructed by ligation or Gibson Assembly and then amplified in E. coli, but bacterial 
transformation reduces the library diversity. By directly transfecting the assembled reaction 
products, the library diversity is limited instead by the number of successfully transfected 
HEK293 producer cells.
Virus production and purification
Recombinant AAVs were generated by triple transfection of 293T cells (ATCC) using 
polyethylenimine (PEI)46. Viral particles were harvested from the media at 72 hrs post 
transfection and from the cells and media at 120 hrs. Cell pellets were resuspended in 10mM 
Tris with 2mM MgCl2, pH 8, freeze-thawed three times, and treated with 100 U/mL 
Benzonase (Epicentre) at 37°C for at least 1 hr. Viral media was concentrated by 
precipitation with 8% polyethylene glycol 8000 (Sigma-Aldrich) with 500 mM sodium 
chloride47, resuspended in Tris-MgCl2, and then added to the lysates. The combined stocks 
were then adjusted to 500 mM NaCl, incubated at 37°C for 30 minutes, and clarified by 
centrifugation at 2000 × g. The clarified stocks were then purified over iodixanol (Optiprep, 
Sigma; D1556) step gradients (15%, 25%, 40% and 60%)48. Viruses were concentrated and 
formulated in phosphate buffered saline (PBS). Virus titers were determined by measuring 
the number of DNaseI-resistant vg using qPCR with linearized genome plasmid as a 
standard46.
For capsid library virus generation, two modifications were made to the above virus 
production protocol to reduce the production of mosaic capsids that could arise from the 
presence of multiple capsid sequences in the same cell. First, only 10 ng of the rAAV-Cap-
in-cis library plasmid was transfected (per 150 mm dish) to increase the likelihood that most 
transfected cells only received one capsid variant sequence. Second, the virus was collected 
at 48 hrs (media) and 60 hrs (cells and media), rather than at 72 hrs and 120 hrs as described 
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above, to minimize the secondary transduction of producer cells with rAAV library virus 
released into the medium.
Animals
All procedures were approved by the California Institute of Technology Institutional Animal 
Care and Use Committee (IACUC). GFAP-Cre mice expressing Cre under the control of the 
mouse GFAP promoter (012886)23 and C57Bl/6J mice (000664) were purchased from the 
Jackson Laboratory (JAX). Intravenous administration of rAAV vectors was performed by 
injecting the virus into the retro-orbital sinus. Mice were randomly assigned to groups of 
predetermined sample size. No mice were excluded from these analyses. Experimenters 
were not blinded to sample groups.
In vivo selection
For the selections in GFAP-Cre mice, 1×1011 vg of the capsid libraries were injected 
intravenously into adult Cre+ mice of either sex. Seven to eight days post-injection, mice 
were euthanized and the brain and spinal cord were collected. Vector DNA was recovered 
from one hemisphere of the brain and half of the spinal cord using 4-5 ml of Trizol (Life 
Technologies; 15596). To purify viral DNA, the upper aqueous fraction was collected 
according to the manufacturer's extraction protocol. We found that the aqueous fraction 
contains a significant portion of the viral DNA genomes as well as RNA. RNA was then 
digested by treatment with 1 uL of RNase A (Qiagen) at 37 °C overnight. Next, a two-step 
PCR amplification strategy was used to selectively recover Cap sequences from Cre-
recombined genomes. The first amplification step preferentially amplifies Cre-recombined 
rAAV-Cap-in-cis-lox sequences using the primers 9CapF and CDF (see Supplementary 
Fig. 1). The PCR was performed for 20-26 cycles of 95°C for 20 sec, 60°C for 20 sec and 
72°C for 30 sec using Q5 Hot Start High-fidelity DNA Polymerase. The PCR product was 
then diluted 1:10 or 1:100 and then used as a template for a second Cre-independent PCR 
reaction using primers XF and AR (Supplementary Fig. 1C). The second PCR generated 
the fragment that was cloned back into the rAAV-ΔCap-in-cis acceptor plasmid as described 
above. 1 μL of the Gibson Assembly reactions were then diluted 1:10 and transformed into 
SURE2 competent cells (Agilent; 200152) to generate individual clones for sequencing.
Variants that showed evidence of enrichment were cloned into an AAV Rep-Cap plasmid 
and transformed into DH5α competent cells (NEB). The novel AAV Rep-Cap variants, or 
AAV2/9 Rep-Cap as a control, were then evaluated using one of the reporter genomes 
described above.
Vector biodistribution
Six-week-old mice female C57Bl/6 mice were injected intravenously with 1×1011 vg of the 
ssAAV-CAG-GFP vector packaged into the indicated AAV capsid. Animals were randomly 
assigned to groups. 25 days after injection, the mice were euthanized and tissues and 
indicated brain regions were collected and frozen at −80°C. DNA was isolated from the 
tissue samples using Qiagen DNeasy Blood and Tissue kit. Vector genomes were detected 
using PCR primers that bind to the WPRE element and were normalized to mouse genomes 
using primers specific to the mouse glucagon gene. Absolute quantification was performed 
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using serial dilutions of linearized plasmid standards of known concentration46. One 
randomly chosen animal injected with AAV-PHP.B was removed from the bio-distribution 
study for histological analysis.
Tissue preparation, immunohistochemistry and imaging
Mice were anesthetized with Nembutal and transcardially perfused with 0.1 M phosphate 
buffer (PB) at room temperature (RT) at pH 7.4 and then with freshly prepared, ice-cold 4% 
paraformaldehyde (PFA) in PB. Brains were post-fixed in 4% PFA overnight and then 
sectioned by vibratome or cryoprotected and sectioned by cryostat. IHC was performed on 
floating sections with primary and secondary antibodies in PBS containing 10% goat or 
donkey serum and 0.5% Triton X-100 (no detergent was used for GAD67 staining). Primary 
antibodies used were mouse anti-AAV capsid (1:20; American Research Products, 
03-65158, clone B1), rabbit anti-GFP (1:1000; Invitrogen, A11122), chicken anti-GFP 
(1:1000; Abcam, ab13970), mouse anti-CC1 (1:200; Calbiochem, OP80), rabbit anti-GFAP 
(1:1000; Dako, Z0334), mouse anti-NeuN (1:500; Millipore, MAB377), rabbit anti-IbaI 
(1:500; Biocare Medical, CP290), mouse anti-Calbindin D28K (1:200; Sigma, CB-955), 
rabbit anti-Calretinin (1:1000; Chemicon, AB5054), mouse anti-GAD67 (1:1000; Millipore, 
MAB5406), guinea pig anti–MAP2 (1:1000; Synaptic Systems, 188004), mouse anti-
Parvalbumin (1:1000; Sigma), Tyrosine Hydroxlyase (1:1000, Aves) and rabbit anti-CD31 
(1:50; Abcam, ab28364). Primary antibodies incubations were performed for 16-24 hrs at 
RT. The sections were then washed and incubated with secondary Alexa-conjugated 
antibodies (1:1000; Invitrogen) for 2-16 hrs. For capsid detection with the B1 antibody that 
recognizes an internal epitope49, floating sections were treated with 2M HCl for 15 minutes 
at 37°C and then washed extensively with PBS prior to incubation with the primary 
antibody. For some images, the 16-bit green channel (GFP) gamma was adjusted to enable 
visualization (without oversaturation) of both low and high GFP-expressing cells present 
within the same field of view. In all cases, changes to gamma or contrast as well as 
microscope and laser settings remained consistent across sets of images. Images were taken 
with a Zeiss LSM 780 confocal microscope fitted with the following objectives: Fluar 5×/
0.25 M27 Plan-Apochromat 10×/0.45 M27 (working distance 2.0 mm), Plan-Apochromat 
25×/0.8 Imm Corr DIC M27 multi-immersion and LD C-Apochromat 40×/1.1 W Korr and 
Plan-Apochromat 100×/1.46 Oil DIC objectives. 3D MIP images and Supplementary 
Movies were generated with Imaris (Bitplane).
Quantification of cell type-specific transduction
Six-week-old female mice were randomly assigned to groups and injected intravenously 
with 2×1012 vg of ssAAV-CAG-NLS-GFP packaged into AAV9, AAV-PHP.B or AAV-
PHP.A. Three weeks later, the mice were perfused and the brains were processed and 
immunostained for the indicated antigen as described above. The number of animals per 
group was pre-established; no animals were excluded from the analysis. Confocal single-
plane images of the cell type-specific immunostaining and native NLS-GFP fluorescence 
were taken. To prevent bias, images were taken from the indicated matched regions 
identified by viewing only the cell type-specific immunostaining channel, rather than from 
GFP expression, prior to image acquisition. Likewise, cell counting was performed by first 
counting and marking each cell stained by the cell-specific antigen by viewing the IHC 
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channel. Next those marked IHC+ cells that were positive for native GFP fluorescence were 
counted. Due to the stark transduction efficiency differences between capsids, the counting 
was not blinded by group.
Tissue clearing
Mice were perfused as above with 60-80 mL of ice-cold 4% PFA in PB at a flow rate of 14 
mL per minute. The flow rate was then reduced to 2-3 mL/min and continued for 2 hrs at 
RT. The mice were then placed in individual custom-built chambers24 and perfused with 200 
mL of recycling RT 4% acrylamide in PB at 2-3 mL/min overnight followed by a 2-hr 
perfusion flush with PB to remove residual polymers/monomers from the vasculature. The 
polymerization process was initiated by placing the chambers in a 42°C water bath and 
delivering, by perfusion (2-3 mL/min), of 200 mL of recycling, degassed PB containing 
0.25% VA-044 initiator for 2-4 hrs. The mice were then perfused with 8% SDS in PB, pH 
7.5 for 7 days. The SDS containing solution was refreshed two times during the 7 days and 
then flushed out by perfusion of 2 L of non-recirculating PB overnight. Cleared tissue 
samples were mounted in RIMS solution (refractive index of 1.46)24 for imaging.
Generation of cortical spheroids from human iPSC
Human cortical spheroids were generated from iPSC as previously described31. Briefly, 
iPSC lines derived from two healthy control individuals were grown on inactivated mouse 
embryonic fibroblast feeders in the following medium: DMEM/F12, Knockout Serum 20%, 
1 mM non-essential amino acids (1:100), GlutaMax (1:200), β-mercaptoethanol (0.1 mM), 
penicillin and streptomycin (1:100) (Life Technologies). Cultures were regularly tested and 
maintained mycoplasma free. Colonies of iPSCs were detached intact with dispase (0.35 
mg/ml, Invitrogen) and transferred into low-attachment plates in iPSC medium 
supplemented with dorsomorphin (5 μM, Sigma) and SB-431542 (10 μM, Tocris), and the 
medium was changed daily. On day six of in vitro differentiation, neural spheroids were 
transferred to NPC medium (Neurobasal A, B27 without vitamin A, GlutaMax (1:100), 
penicillin and streptomycin; Life Technologies), which was supplemented with EGF (20 
ng/ml) and FGF2 (20 ng/ml) until day 24, and then supplemented with BDNF (20 ng/ml) 
and NT3 (20 ng/ml) from day 25 to 42. From day 43 onwards, cortical spheroids were 
maintained in NPC medium, which was changed every 4 days.
Dissociation and viral infection of cortical spheroids
For enzymatic dissociation and culture in monolayer, cortical spheroids at day 170-200 of in 
vitro differentiation (two independent neural differentiations of one iPSC line from one 
individual and one differentiation of an iPSC line from another individual) were incubated 
with Accutase (Innovative Cell Technologies) for 25 min at 37°C, washed three times with 
NPC media and gently triturated with a P-200 pipette. Cells were plated on poly-ornithine 
and laminin coated glass coverslip (15 mm) at ~300,000 cells/well and maintained in NPC 
media supplemented with BDNF (20 ng/ml) and NT3 (20 ng/ml) for the first 24 hrs, and 
then maintained in NPC media without growth factors.
Cultures grown on coverslips were infected with each of the viruses at a titer of 1×109 vg/
well and fixed 5 days later with 4% paraformaldehyde (PFA) for 10 min. For 
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immunocytochemistry, cells were permeabilized with 0.2% Triton X-100 for 10 min and 
blocked with 10% goat serum in PBS for 1 hr. Coverslips were then incubated with 
antibodies diluted in blocking solution for 2 hr. Nuclei were visualized with Hoechst 33258 
(Life Technologies, 1:10,000).
Cells were imaged with a Zeiss M1 Axioscope using a 40× objective. The proportion of 
GFP+ cells co-labeled with either GFAP or MAP2 was quantified in images of 10 random 
fields per coverslip for each experimental condition. Results presented are the average of 
two separate dissociation and infection experiments.
To infect intact 3D cultures with AAVs, single human cortical spheroids at day 197 days of 
in vitro differentiation were transferred overnight into 1.5 ml Eppendorf tubes containing 
6×109 vg/400 μl in NPC media, and were fixed 7 days later in 4% PFA overnight. Fixed 
spheroids were then transferred into 30% sucrose for 24 hrs, embedded in O.C.T. (Fisher 
Scientific) and cut at 14 μm sections. For immunohistochemistry, sections were blocked with 
10% goat serum in PBS containing 0.3% Triton-X100 for 1 hr. Images were collected with a 
Leica TCS SP8 confocal microscope.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Cre-dependent recovery of AAV capsid sequences from transduced target cells
(a) An overview of the CREATE selection process. PCR is used to introduce diversity (full 
visual spectrum vertical band) into a capsid gene fragment (yellow). The fragment is cloned 
into the rAAV genome harboring the remaining capsid gene (gray) and is used to generate a 
library of virus variants. The library is injected into Cre transgenic animals and PCR is used 
to selectively recover capsid sequences from Cre+ cells. (b) The rAAV-Cap-in-cis-lox rAAV 
genome. Cre inverts the polyadenylation (pA) sequence flanked by the lox71 and lox66 
sites. PCR primers (half arrows) are used to selectively amplify Cre-recombined sequences. 
(c) PCR products from Cre recombination-dependent (top) and -independent (bottom) 
amplification of capsid library sequences recovered from two Cre+ or Cre− mice are shown. 
Schematics (bottom) show the PCR amplification strategies (see Supplementary Fig. 1 for 
details). (d) Schematic shows the AAV genes within the Rep-AAP AAV helper plasmid and 
the proteins encoded by the cap gene. Stop codons inserted in the cap gene eliminate VP1, 
VP2 and VP3 capsid protein expression. (e) DNase-resistant AAV vector genomes (vg) 
produced with the split AAV2/9 rep-AAP and rAAV-Cap-in-cis-lox genome (top) as 
compared to the vg produced with standard AAV2/9 rep-cap helper and rAAV-UBC-
mCherry genome (middle) or with the AAV2/9 rep-AAP and rAAV-UBC-mCherry genome 
(bottom). N=3 independent trials per group; mean ± s.d.; **p<0.01, ***p<0.001; one-way 
ANOVA and Tukey multiple comparison test. (f) Cloning the 7-mer capsid library into the 
rAAV-ΔCap-in-cis vector. (g) The AAV9 surface model shows the location of the 7-mer 
inserted between AA588-589 (magenta). Sites encoded with the PCR-generated library 
fragment (AA450-592) are shown in yellow.
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Figure 2. AAV-PHP.B mediates efficient gene delivery throughout the CNS after intravenous 
injection in adult mice
(a-f) ssAAV9:CAG-GFP or ssAAV-PHP.B:CAG-GFP, at 1×1012 vg/mouse or 1×1011 (a, 
right), was intravenously injected into adult mice. Images show GFP expression 3 weeks 
after injection. (a) Representative images of GFP IHC in the brains of mice given AAV9 
(left) or AAV-PHP.B (middle and right). (b) Native GFP fluorescence in the cortex (left) or 
striatum (right) in 50 μm maximum intensity projection (MIP) confocal images. (c) GFP 
fluorescence in the PARS-cleared24 lumbar spinal cord. (d) GFP fluorescence in the retina 
(left: 20 μm MIP, transverse section; right: whole-mount MIP). (e,f) GFP fluorescence in 3D 
MIP images of PARS-cleared tissue from AAV-PHP.B transduced cortex and striatum (e) 
and indicated organs from mice transduced with AAV9 (top) or AAV-PHP.B (bottom) (f). 
Arrows highlight GFP+ nerves. Asterisks in the image of the pancreas highlight GFP+ islet 
cells. Major tick marks in 3D projections are 100 μm. (g) AAV biodistribution in the 
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indicated brain regions (top) and organs (bottom) 25 days after intravenous injection of 
1×1011 vg into adult mice. N=3 for AAV-PHP.B and n=4 for AAV9; mean ± s.d.; **p<0.01, 
***p<0.001, unpaired t tests corrected for multiple comparisons by the Holm-Sidak method. 
Scale bars: 1 mm (a, c (left)); 50 μm (b, c (right), d, e). Major tick marks in 3D projections 
in c, e, f are 100 μm.
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Figure 3. AAV-PHP.B transduces multiple CNS cell types more efficiently than AAV9
(a-e) AAV-PHP.B transduces astrocytes, oligodendrocytes and neurons. Images show GFP 
expression 3 weeks after intravenous injection of 1×1011 (a) or 1×1012 (b-e) of ssAAV-
PHP.B:CAG-GFP into adult mice. (a) MIP image of GFP (green) and GFAP (magenta) IHC 
in the hippocampus. (b) GFP and CC1 (magenta) IHC in the cortex. Numbered boxes 
highlight examples of double positive cells. Corresponding single-channel images are shown 
(right). Asterisks highlight cells without detectable GFP expression. (c) GFP and NeuN IHC 
in the indicated brain region. (d) MIP image of GFP fluorescence and TH IHC in the 
midbrain. (e) GFP and Calbindin (Calb) IHC in the cerebellum. (f-h) Quantification of the 
percentage of cells positive for NLS-GFP in the indicated brain region 3 weeks post 
injection. (i) AAV-PHP.B transduces ChAT+ spinal motor neurons. Images show native 
NLS-GFP fluorescence and IHC for ChAT in whole transverse spinal cord sections (left) or 
ventral horn MIP image (right). The percentage of ChAT+ neurons that expressed NLS-GFP 
in each spinal cord region is given ± the 95% confidence interval. For quantification, n=5 per 
group; mean ± s.d; All pairs of AAV9 vs AAV-PHP.B means were found to be different 
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(***p<0.001) unpaired t tests corrected for multiple comparisons by the Holm-Sidak 
method. Scale bars: 20 μm (a,b,d), 50 μm (c,i, right), 200 μm (e) and 1 mm (i, left).
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Figure 4. AAV-PHP.A exhibits efficient transduction of CNS astrocytes and reduced tropism for 
peripheral organs
(a-c, e) Images show GFP expression 3 weeks after intravenous injection of 3×1011 of 
ssAAV9:CAG-GFP or ssAAV-PHP.A:CAG-GFP into adult mice. (a,b) Representative 
images of GFP IHC. (c) GFP IHC (green) and GFAP IHC (magenta) in the hippocampus. 
Numbered boxes highlight examples of GFP+/GFAP+ cells. Corresponding single-channel 
images are shown on the right. (d) 2.5×1011 vg of ssAAV-PHP.A:CAG-NLS-GFP was 
injected intravenously into adult mice. Graphs show quantification of the percentage of 
Aldh1L1+ (blue) and NeuN+ cells (orange) positive for NLS-GFP. (e) Native GFP 
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expression in the liver (green) and tissue autofluorescence (magenta). (f) AAV 
biodistribution in the brain (top) and peripheral organs (bottom) 25 days after intravenous 
injection of 1×1011 vg into adult mice. (e, f) N=4 per group; mean ± s.d; *p<0.05, **p<0.01, 
***p<0.001, unpaired t tests corrected for multiple comparisons by the Holm-Sidak method. 
Scale bars: 1 mm (a); 100 μm (b); 50 μm (c).
Deverman et al. Page 21
Nat Biotechnol. Author manuscript; available in PMC 2016 October 31.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
